Overview of The Incidence of Hyperprolactinemia Side Effects in Schizophrenia Patients With Antipsychotic Therapy

Vivinia RA Putri, Dita Hasni, Nadia Purnama Dewi, Mutiara Anissa

Abstract


Antipsychotic-induced hyperprolactinemia disorder affects the morbidity and quality of life of the patient, and can lower the patient's adherence to taking antipsychotics, thereby lowering the therapeutic success rate. This study aims to figure out the incidence of hyperprolactinemia side effects in schizophrenia patients receiving antipsychotic therapy. This descriptive research was conducted at HB Saanin Psychiatric Hospital  Padang in January-June 2018. The population in this study is all schizophrenia patients in the HB. Saanin Psychiatric Hospital Padang Year 2018 and involved participants as many as 100 people recruited in consecutive sampling. Data were analyzed using a descriptive statistical method. The results showed that more than half of the patients were 59 people (59.0%) hyperprolactinemia. Patients with gynecomastia amounted to 16 people (16%). Patients with galactorrhea amounted to 3 people (3%). Patients with sexual dysfunction amounted to 19 people (19%). Male patients amounted to 60 people, 21 people (35%) The sexual dysfunction of female patients amounted to 40 people, 26 people (65%) Menstrual cycle changes. More than half of the Schizophrenia patients receiving antipsychotic therapy in this study suffer symptoms of hyperprolactinemia in the manifestation of galactorrhea, gynecomastia, menstrual disorders, and sexual dysfunction.

Keywords


Antipsychotic, Hyperprolactinemia, Schizophrenia

DOI:

https://doi.org/10.30596/bf.v5i2.3761


Full Text:

PDF

References


Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nat Rev Dis Prim. 2015 Nov 12;1.

Zahnia S, Wulan Sumekar D. Kajian Epidemiologic Skizofrenia. Majority [Internet]. 2016;5(5):160–6. Available from: http://juke.kedokteran.unila.ac.id/index.php/majority/article/view/904/812

WHO. WHO | Schizophrenia. Schizophrenia. 2015.

RISKESDAS. Hasil Utama Riset Kesehatan Dasar 2018. Kementrian Kesehat Republik Indones. 2018;

Nandinanti IN, Yaunin Y, Nurhajjah S. Efek Electro Convulsive Therapy (ECT) terhadap Daya Ingat Pasien Skizofrenia di RSJ Prof. HB. Sa’anin Padang. J Kesehat Andalas. 2015;4(3):883–8.

Chue P, Agyapong V, Abba-Aji A. Antipsychotic Drugs. In: Side Effects of Drugs Annual. 2018. p. 99–119.

Barnes TRE. Neuroscience Perspectives Antipsychotic Drugs and their Side- Effects Series editor : Peter Jenner. Bloom FE, Brown DA, Carlsson A, Costa E, Fuxe K, Gessa GL, editors. Elsevier Science;

Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Curr Neuropharmacol. 2017;16(8):1210–23.

Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Hyperprolactinémies induites par les antipsychotiques : physiopathologie, clinique et surveillance. Encephale [Internet]. 2014 Feb [cited 2020 May 18];40(1):86–94. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0013700612000449

Carvalho MM de, Góis C. [Hyperprolactinemia in mentally ill patients]. Acta Med Port [Internet]. 2011 [cited 2020 May 18];24(6):1005–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22713195

Ignjatović Ristić D, Cohen D, Obradović A, Nikić-Đuričić K, Drašković M, Hinić D. The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. Nord J Psychiatry [Internet]. 2018;72(2):124–9. Available from: https://doi.org/10.1080/08039488.2017.1400097

Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics - A review. Human Psychopharmacology. 2010.

Majumdar A, Mangal NS. Hyperprolactinemia. Journal of Human Reproductive Sciences. 2013.

Binart N. Prolactin [Internet]. The Pituitary: Fourth Edition. Elsevier Inc.; 2017. 129–161 p. Available from: http://dx.doi.org/10.1016/B978-0-12-804169-7.00005-2

Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs. 2004;64(20):2291–314.

Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs. 2014;28(5):421–53.

Sathish Kumar S V., Sinha VK. Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. Indian J Psychiatry. 2015 Oct 1;57(4):386–91.

O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008 Mar;22(2 SUPPL.):70–5


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

BULETIN FARMATERA

Gedung Kampus 1 Fakultas Kedokteran Universitas Muhammadiyah Sumatera Utara | UMSU

Lantai II,Laboratorium Farmakologi dan Terapi FK UMSU-Jalan Gedung Arca No. 53 Medan-Sumatera Utara ,

Kode Pos 20217 Kontak: 0812-6208-2844,E-mail: farmatera@umsu.ac.id


 
Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
View My Stats Buletin Farmatera